Phase 3 Readout

ORMP: Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua

Name: Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua
Start: 2027-05-22
End: 2027-05-22

May 22, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: May 22, 2027
Company: ORAMED PHARMACEUTICALS INC. (ORMP)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua

May 22, 2027

ORMP overview →

Company: ORAMED PHARMACEUTICALS INC. (ORMP)
Indication: Type 2 Diabetes Mellitus